Recent CDC data show that that wastewater SARS-CoV-2 detections are high and that LP.8.1 and related strains XFG and NB.1.8.1 ...

Moderna (MRNA) announced “positive” preliminary immunogenicity data for the 2025-2026 formula of Spikevax, which targets the LP.8.1 variant of ...

Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) announced clinical trial data to reaffirm the effectiveness and safety of their messenger RNA-based COVID shots on Tuesday after President Donald Trump ...

Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in ...

CAMBRIDGE, MA / ACCESS Newswire / September 2, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that five abstracts on its investigational mRNA therapeutics have been accepted for presentation at ...

Preliminary results from an ongoing Phase IV trial showed that Moderna’s updated 2025-2026 Spikevax vaccine generated a ...

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent ...

Moderna and Novavax issued responses to President Trump’s demands for information about the COVID-19 vaccines.

Pfizer and Moderna shares fell after reports said Trump officials plan to link Covid vaccines to child deaths at a key CDC ...

Pfizer (PFE) stock in focus as the company plans to release new data on its updated COVID vaccine developed with BioNTech (BNTX) after Trump’s criticism. Read more here.